TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%
TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were down 9.8% during mid-day trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 1,500 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 58,702 shares. The stock had previously closed at $0.13.
TC 生物製藥 (控股) 有限公司 (NASDAQ: TCBPW — 獲得評級) 股份下跌 9.8% 週五中午交易期間.該股票的交易價格低至 0.11 美元，最後交易價格為 0.11 美元。在日間交易期間，約 1,500 股成交手，較 58,702 股的平均日交易量下降 97%。該股票之前已收盤 0.13 美元。
TC Biopharm Stock Down 9.8 %
TC 生物製藥庫存下跌 9.8%
The firm's fifty day moving average is $0.14 and its 200-day moving average is $0.15.
該公司的五十天移動平均線為 0.14 美元，其 200 天移動平均線為 0.15 美元。
Institutional Trading of TC Biopharm
TC 生物製藥的機構交易
An institutional investor recently bought a new position in TC Biopharm stock. Nantahala Capital Management LLC bought a new position in shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,294 shares of the company's stock, valued at approximately $117,000.
一名機構投資者最近購買了 TC 生物製藥股票的新倉位。根據其最近向證券交易委員會（SEC）提交的 13F 表格，南大哈拉資本管理有限責任公司在第一季度購買了 TC 生物製藥（控股）有限公司（NASDAQ：TCBPW-獲得評級）的股份的新頭寸。該機構投資者購買了該公司股票的 235,294 股，價值約為 11 萬美元。
TC Biopharm Company Profile
TC 生物製藥公司簡介
(Get Rating)
(取得評分)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
TC 生物醫藥（控股）有限公司是一家臨床階段生物製藥公司，致力於開發基於同種異體伽瑪三角量 T 細胞平台的免疫治療產品。其產品管線包括用於治療急性髓細胞白血病的未改性細胞療法；用於治療 COVID-19 的免疫性細胞療法；用於治療的未改性細胞療法；用於 GI 道癌症治療的 TCB009；以及作為異體共生刺激 GD-T CAR 臨床前藥物候選藥物的 TCB005/TCB006，以及針對各種腫瘤類型表達的抗原的 TCB005/TCB006。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don't Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- 索取有關 TC 生物製藥研究報告的免費副本
- 這種具有巨大增長前景的小技術正接近買點
- 不要追逐聯邦快遞更高，等待回調
- 3 個防禦性技術投資組合的股票
- 牛奶這些 3 現金奶牛的股息
- 歐洲提高利率，美聯儲應該跟隨嗎？
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
接收 TC 生物製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 TC 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。